Literature DB >> 28762862

A clinician's guide to ADHD treatment options.

Gregory W Mattingly1,2, Joshua Wilson3, Anthony L Rostain4.   

Abstract

Attention deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition of children and adolescents that often persists into adulthood. Primary care physicians are commonly the first to diagnosis ADHD and initiate a treatment plan with the patient. Guidelines recommend psychostimulant treatment as a first-line therapy in the management plan because it has a substantial impact on alleviating the core symptoms of ADHD. The recent development of a variety of methylphenidate and amphetamine formulations provides many options to meet individual patient lifestyle needs. Liquid, chewable, sprinkled capsule, wearable patch, and orally disintegrating tablet formulations are currently available for patients who may be noncompliant with or have difficulty swallowing traditional pills. This review provides a resource for physicians to identify the stimulant delivery formulation that best suits the patient. Formulations in development are also discussed.

Entities:  

Keywords:  ADHD; amphetamine; drug delivery; methylphenidate; psychiatry; psychostimulant

Mesh:

Substances:

Year:  2017        PMID: 28762862     DOI: 10.1080/00325481.2017.1354648

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  7 in total

1.  CK1δ over-expressing mice display ADHD-like behaviors, frontostriatal neuronal abnormalities and altered expressions of ADHD-candidate genes.

Authors:  Mingming Zhou; Jodi Gresack; Jia Cheng; Kunihiro Uryu; Lars Brichta; Paul Greengard; Marc Flajolet
Journal:  Mol Psychiatry       Date:  2018-10-19       Impact factor: 15.992

2.  A comparative study on the neurophysiological mechanisms underlying effects of methylphenidate and neurofeedback on inhibitory control in attention deficit hyperactivity disorder.

Authors:  Annet Bluschke; Julia Friedrich; Marie Luise Schreiter; Veit Roessner; Christian Beste
Journal:  Neuroimage Clin       Date:  2018-10-25       Impact factor: 4.881

3.  Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study.

Authors:  Andrew J Cutler; Katsumi Suzuki; Brittney Starling; Kanan Balakrishnan; Marina Komaroff; Mariacristina Castelli; Suzanne Meeves; Ann C Childress
Journal:  J Child Adolesc Psychopharmacol       Date:  2022-01-11       Impact factor: 2.576

4.  Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment.

Authors:  M Janelle Cambron-Mellott; Jaromir Mikl; Joana E Matos; Jennifer G Erensen; Kathleen Beusterien; Marc J Cataldo; Bernadette Hallissey; Gregory W Mattingly
Journal:  Patient Prefer Adherence       Date:  2021-05-21       Impact factor: 2.711

5.  Perception-Action Integration Is Modulated by the Catecholaminergic System Depending on Learning Experience.

Authors:  Elena Eggert; Annet Bluschke; Adam Takacs; Maximilian Kleimaker; Alexander Münchau; Veit Roessner; Moritz Mückschel; Christian Beste
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-23       Impact factor: 5.176

6.  A novel approach to intra-individual performance variability in ADHD.

Authors:  Annet Bluschke; Nicolas Zink; Moritz Mückschel; Veit Roessner; Christian Beste
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-05-14       Impact factor: 4.785

7.  Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults.

Authors:  Martin A Katzman; Greg Mattingly; Larry J Klassen; Marc J Cataldo; Graeme A E Donnelly
Journal:  J Clin Psychopharmacol       Date:  2020 Nov/Dec       Impact factor: 3.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.